Truist lowered the firm’s price target on UnitedHealth (UNH) to $345 from $360 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results for Healthcare Services. The quarter should reflect an ongoing mixed, sector-dependent backdrop across the firm’s coverage universe with a focus on selectivity and utilization-leveraged names best positioned, and Managed Care continuing to face challenges, the analyst tells investors in a research note. Truist adds that it remains bullish on core demand drivers for the industry however and also believes that the Reconciliation Bill has provided increased clarity around regulatory framework.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- CVS Snatches CalPERS Pharmacy Contract from UnitedHealth
- UnitedHealth Stock (UNH) Down as $3.3B Secret Sales Raise Eyebrows
- ‘Proceed with Caution,’ Top Analyst Cuts UnitedHealth Stock’s (UNH) Price Target
- Trump slaps 30% tariffs on EU and Mexico, announces Russia tariffs: Morning Buzz
- Trump Trade: U.S. slaps 30% tariff rate on EU, Mexico